CDK3 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 20 of 179 results for "CDK3"
i
  1. Cyclin C-CDK3/8/19 kinases play a tumor-suppressive role in vivo ArrayExpress

    ID: E-GEOD-58712

    Description: n “orphan” CDK19 kinase, as well as CDK8 and CDK3. These cyclin C-CDK complexes phosphorylate Notch1 intracellular domain (ICN1), which allows binding of ICN1 to Fbw7 and triggers ICN1 polyubiquitination. Genetic ablation of cyclin C blocks ICN1 phosphorylation, disrupts Fbw7 binding, and decreases ICN1 ubiquitination in vivo, thereby strongly elevating ICN1 levels in several compartments of cyclin C knockout mice. Ablation of cyclin C, or cyclin C heterozygosity collaborate with other oncogenic lesions and accelerate development of T-cell acute lymphoblastic leukemia (T-ALL) in cyclin Cdeficient mice. Furthermore, the locus encoding cyclin C is heterozygously deleted in a significant fraction of human T-ALL, and these tumors express reduced cyclin C levels. ...

  2. Cyclin C-CDK3/8/19 kinases play a tumor-suppressive role in vivo OmicsDI

    ID: PXD001237

    Date Released: 07-06-2016

    Description: “orphan” CDK19 kinase14, as well as CDK8 and CDK3. These cyclin C-CDK complexes phosphorylate Notch1 intracellular domain (ICN1), which allows binding of ICN1 to Fbw7 and triggers ICN1 polyubiquitination. Genetic ablation of cyclin C blocks ICN1 phosphorylation, disrupts Fbw7 binding, and decreases ICN1 ubiquitination in vivo, thereby strongly elevating ICN1 levels in several compartments of cyclin C knockout mice. Cyclin C was cloned as a growth-promoting G1 cyclin1,2, and several studies postulated a role for cyclin C in driving cell proliferation3-8 . Moreover, cyclin C, together with its kinase partner, the cyclin-dependent kinase CDK8, is believed to represent an essential component of basal transcriptional machinery where it globally represses gene expression9-13. H...

  3. miR-126 governs human leukemia stem cell quiescence and therapeutic resistance ArrayExpress

    ID: E-GEOD-55770

    Description: t through suppression of the G0 to G1 gatekeeper, CDK3. Thus, in AML, miRNAs influence patient outcome through post-transcriptional regulation of stemness programs in LSC. 74 primary patient normal karyotype AML samples were analyzed for miRNA expression....

  4. Cyclin C-CDK3/8/19 kinases play a tumor-suppressive role in vivo OmicsDI

    ID: E-GEOD-58712

    Date Released: 09-06-2014

    Description: n “orphan” CDK19 kinase, as well as CDK8 and CDK3. These cyclin C-CDK complexes phosphorylate Notch1 intracellular domain (ICN1), which allows binding of ICN1 to Fbw7 and triggers ICN1 polyubiquitination. Genetic ablation of cyclin C blocks ICN1 phosphorylation, disrupts Fbw7 binding, and decreases ICN1 ubiquitination in vivo, thereby strongly elevating ICN1 levels in several compartments of cyclin C knockout mice. Ablation of cyclin C, or cyclin C heterozygosity collaborate with other oncogenic lesions and accelerate development of T-cell acute lymphoblastic leukemia (T-ALL) in cyclin Cdeficient mice. Furthermore, the locus encoding cyclin C is heterozygously deleted in a significant fraction of human T-ALL, and these tumors express reduced cyclin C levels. ...

  5. Cyclin C is a haploinsufficient tumour suppressor BioProject

    ID: PRJNA253212

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: tes an 'orphan' CDK19 kinase, as well as CDK8 and CDK3. These cyclin-C-CDK complexes phosphorylate the Notch1 intracellular domain (ICN1) and promote ICN1 degradation. Genetic ablation of cyclin C blocks ICN1 phosphorylation in vivo, thereby elevating ICN1 levels in cyclin-C-knockout mice. Cyclin C ablation or heterozygosity collaborates with other oncogenic lesions and accelerates development of T-cell acute lymphoblas...
  6. miR-126 governs human leukemia stem cell quiescence and therapeutic resistance BioProject

    ID: PRJNA240981

    Keywords: Other

    Access Type: download

    dataset.description: t through suppression of the G0 to G1 gatekeeper, CDK3. Thus, in AML, miRNAs influence patient outcome through post-transcriptional regulation of stemness programs in LSC. Overall design: 74 primary patient normal karyotype AML samples were analyzed for miRNA expression....
  7. miR-126 governs human leukemia stem cell quiescence and therapeutic resistance [Illumina] BioProject

    ID: PRJNA241048

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: t through suppression of the G0-to-G1 gatekeeper, CDK3. Thus, in AML, miRNAs influence patient outcome through post-transcriptional regulation of stemness programs in LSC. Overall design: Total RNA was extracted from 8227 cells and treated with miR-126 sponge or miR-126-containing viral particles (and corresponding controls)....
  8. ATF1_MOUSE UniProt:Swiss-Prot

    ID: P81269

    Description: sic motif Leucine-zipper Phosphoserine; by CaMK1, CDK3, RPS6KA4 and RPS6KA5 Phosphoserine; by HIPK2...

  9. ATF1_BOVIN UniProt:Swiss-Prot

    ID: Q08DA8

    Description: sic motif Leucine-zipper Phosphoserine; by CaMK1, CDK3, RPS6KA4 and RPS6KA5 Phosphoserine; by HIPK2...

  10. Aerobic training modulation of the host systemic milieu directly alters breast cancer cell phenotype in vitro ArrayExpress

    ID: E-GEOD-46925

    Description: ferential modulation of 310 genes including PTEN, CDK3, and IGFBP1. Our findings indicate the widespread potential of chronic aerobic training to modulate host immune-inflammatory systemic factors in patients with solid tumors. Modulation of such pathways directly alters breast cancer phenotypes providing novel insight into the molecular pathways by which exercise may inhibit malignant progression. MDA-MB-231 cells were plated at 250,000 cells/well in triplicate with 10% FBS in 6-well plates and left overnight to adhere. Media was suctioned off and replaced with serum free media. Patient serum was then added to the wells at a 10% final concentration and RNA was harvested using Qiagen RNeasy kit after 4 days....

  11. miR-126 Governs Human Leukemia Stem Cell Quiescence and Therapeutic Resistance [miRNA] BioProject

    ID: PRJNA241402

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: f human LSC. By targeting the G0 to G1 gatekeeper CDK3, miR-126 preserved LSC quiescence and promoted chemotherapy resistance. Thus, in AML, miRNAs influence patient outcome through post-transcriptional regulation of stemness programs in LSC. Overall design: Peripheral blood from 24 AML patients and 3 human lin-CB pools were thawed, stained for CD34/CD38 cell surface markers and sorted into 4 populations. A total of 13 AML patient samples were functionally validated for leukemia-initiating capacity by xenotransplanation into immunodeficient mice. Global miRNA profiling was performed on all sorted AML samples and 3 lin-CB samples. An LSC miRNA signature was derived by infomatically testing engrafting fractions against non-engrafting fractions....
  12. Aerobic training modulation of the host systemic milieu directly alters breast cancer cell phenotype in vitro. BioProject

    ID: PRJNA203043

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: ferential modulation of 310 genes including PTEN, CDK3, and IGFBP1. Our findings indicate the widespread potential of chronic aerobic training to modulate host immune-inflammatory systemic factors in patients with solid tumors. Modulation of such pathways directly alters breast cancer phenotypes providing novel insight into the molecular pathways by which exercise may inhibit malignant progression. Overall design: MDA-MB-231 cells were plated at 250,000 cells/well in triplicate with 10% FBS in 6-well plates and left overnight to adhere. Media was suctioned off and replaced with serum free media. Patient serum was then added to the wells at a 10% final concentration and RNA was harvested using Qiagen RNeasy kit after 4 days....
  13. miR-126 Governs Human Leukemia Stem Cell Quiescence and Therapeutic Resistance OmicsDI

    ID: PXD001994

    Date Released: 03-31-2016

    Description: f human LSC. By targeting the G0 to G1 gatekeeper CDK3, miR-126 preserved LSC quiescence and promoted chemotherapy resistance. Thus, in AML, miRNAs influence patient outcome through post-transcriptional regulation of stemness programs in LSC....

  14. miR-126 governs human leukemia stem cell quiescence and therapeutic resistance OmicsDI

    ID: E-GEOD-55770

    Date Released: 02-07-2016

    Description: t through suppression of the G0 to G1 gatekeeper, CDK3. Thus, in AML, miRNAs influence patient outcome through post-transcriptional regulation of stemness programs in LSC. 74 primary patient normal karyotype AML samples were analyzed for miRNA expression....

  15. Cyclin C-CDK3/8/19 kinases play a tumor-suppressive role in vivo ProteomeXchange

    ID: PXD001237

    Instrument: Q Exactive

    Date Released: 07-06-2016

  16. Aerobic training modulation of the host systemic milieu directly alters breast cancer cell phenotype in vitro. OmicsDI

    ID: E-GEOD-46925

    Date Released: 08-21-2015

    Description: ferential modulation of 310 genes including PTEN, CDK3, and IGFBP1. Our findings indicate the widespread potential of chronic aerobic training to modulate host immune-inflammatory systemic factors in patients with solid tumors. Modulation of such pathways directly alters breast cancer phenotypes providing novel insight into the molecular pathways by which exercise may inhibit malignant progression. MDA-MB-231 cells were plated at 250,000 cells/well in triplicate with 10% FBS in 6-well plates and left overnight to adhere. Media was suctioned off and replaced with serum free media. Patient serum was then added to the wells at a 10% final concentration and RNA was harvested using Qiagen RNeasy kit after 4 days....

  17. BMS-536924 KINOMEscan LINCS

    Data Type: Binding Protein binding profile

    Assay: KINOMEscan kinase-small molecule binding assay

    Biological Process: Small molecule metabolic process

    ID: LDS-1098

    protein.name: CDK3
  18. ALW-II-49-7 KINOMEscan LINCS

    Data Type: Binding Protein binding profile

    Assay: KINOMEscan kinase-small molecule binding assay

    Biological Process: Small molecule metabolic process

    ID: LDS-1036

    protein.name: CDK3
  19. GDC-0941 KINOMEscan LINCS

    Data Type: Binding Protein binding profile

    Assay: KINOMEscan kinase-small molecule binding assay

    Biological Process: Small molecule metabolic process

    ID: LDS-1046

    protein.name: CDK3
  20. NVP-TAE684 KINOMEscan LINCS

    Data Type: Binding Protein binding profile

    Assay: KINOMEscan kinase-small molecule binding assay

    Biological Process: Small molecule metabolic process

    ID: LDS-1095

    protein.name: CDK3

Displaying 20 of 179 results for "CDK3"